Results 1 to 10 of about 537,211 (318)

Fine-tuning the antigen sensitivity of CAR T cells: emerging strategies and current challenges

Frontiers in Immunology, 2023
Chimeric antigen receptor (CAR) T cells are “living drugs” that specifically recognize their target antigen through an antibody-derived binding domain resulting in T cell activation, expansion, and destruction of cognate target cells.
Dennis Christoph Harrer, Dennis Christoph Harrer, Sin-Syue Li, Sin-Syue Li, Marcell Kaljanac, Markus Barden, Hong Pan, Hinrich Abken   +7 more
doaj   +1 more source

CAR Triggered Release of Type-1 Interferon Limits CAR T-Cell Activities by an Artificial Negative Autocrine Loop

Cells, 2022
The advent of chimeric antigen receptor (CAR) T cells expedited the field of cancer immunotherapy enabling durable remissions in patients with refractory hematological malignancies.
Dennis Christoph Harrer, Charlotte Schenkel, Valerie Bezler, Marcell Kaljanac, Jordan Hartley, Markus Barden, Hong Pan, Astrid Holzinger, Wolfgang Herr, Hinrich Abken   +9 more
doaj   +1 more source

Food allergy immunotherapy: Oral immunotherapy and epicutaneous immunotherapy [PDF]

Allergy, 2020
AbstractIgE‐mediated food allergy remains a significant and growing problem across the globe. Of the various treatment modalities, oral immunotherapy (OIT) and epicutaneous immunotherapy (EPIT) have been the best studied. Across various studies of OIT for egg, milk, and peanut allergy, strong levels of desensitization have been shown.
Edwin H. Kim, Arvil Wesley Burks
openaire   +2 more sources

Anti-TACI single and dual-targeting CAR T cells overcome BCMA antigen loss in multiple myeloma

Nature Communications, 2023
Chimeric Antigen Receptor (CAR) T cells directed to B cell maturation antigen (BCMA) mediate profound responses in patients with multiple myeloma, but most patients do not achieve long-term complete remissions.
Rebecca C. Larson, Michael C. Kann, Charlotte Graham, Christopher W. Mount, Ana P. Castano, Won-Ho Lee, Amanda A. Bouffard, Hana N. Takei, Antonio J. Almazan, Irene Scarfó, Trisha R. Berger, Andrea Schmidts, Matthew J. Frigault, Kathleen M. E. Gallagher, Marcela V. Maus   +14 more
doaj   +1 more source

Oncolytic Virus Immunotherapy [PDF]

, 2021
Oncolytic viruses (OVs) were originally developed as direct cytotoxic agents but have been increasingly recognised as a form of immunotherapy [...
Carolina S. Ilkow, Antonio Marchini, Alan Melcher   +2 more
core   +1 more source

The loss of B7-H4 expression in breast cancer cells escaping from T cell cytotoxicity contributes to epithelial-to-mesenchymal transition

Breast Cancer Research, 2023
Background B7 homology 4 (B7-H4), a potential target for cancer therapy, has been demonstrated to inhibit T cell cytotoxicity in the early stages of breast cancer.
Linlin Zhou, Jichun Wu, Mei Ruan, Yonglei Xiao, Hailin Lan, Qiongwen Wu, Chen-Wei Yu, Qiuyu Zhang   +7 more
doaj   +1 more source

The Next-Generation of Combination Cancer Immunotherapy: Epigenetic Immunomodulators Transmogrify Immune Training to Enhance Immunotherapy [PDF]

, 2021
Cancer immunotherapy harnesses the immune system by targeting tumor cells that express antigens recognized by immune system cells, thus leading to tumor rejection.
Narges Baluch, Neda Ashayeri, Qorri, Bessi, Kumar, Sushil, Das, Bikul, Cheng, Hai-Ling Margaret, Manpreet Sambi, Szewczuk, Myron R., Sambi, Manpreet, Hai-Ling Margaret Cheng, Ashayeri, Neda, Bikul Das, Myron R. Szewczuk, Herman Yeger, Bessi Qorri, Sushil Kumar, Yeger, Herman, Baluch, Narges, Mokhtari, Reza Bayat, Reza Bayat Mokhtari   +19 more
core   +2 more sources

The Renewal of Cancer Immunotherapy [PDF]

, 2023
Cancer immunotherapy embraces many current, promising therapeutic approaches to eradicate tumors by activating host antitumor activity [...
Jenny Bulgarelli, Laura Ridolfi, Sara Pignatta, Massimiliano Petrini   +3 more
core   +1 more source

Intratumoral co‐injection of NK cells and NKG2A‐neutralizing monoclonal antibodies

EMBO Molecular Medicine, 2023
NK‐cell reactivity against cancer is conceivably suppressed in the tumor microenvironment by the interaction of the inhibitory receptor NKG2A with the non‐classical MHC‐I molecules HLA‐E in humans or Qa‐1b in mice.
Ignacio Melero, Maria C Ochoa, Carmen Molina, Sandra Sanchez‐Gregorio, Saray Garasa, Carlos Luri‐Rey, Sandra Hervas‐Stubbs, Noelia Casares, Edurne Elizalde, Gabriel Gomis, Assunta Cirella, Pedro Berraondo, Alvaro Teijeira, Maite Alvarez   +13 more
doaj   +1 more source

IRF4 downregulation improves sensitivity and endurance of CAR T cell functional capacities

Frontiers in Immunology, 2023
Chimeric antigen receptor (CAR) modified T cells can induce complete remissions in patients with advanced hematological malignancies. Nevertheless, the efficacy is mostly transient and remains so far poor in the treatment of solid tumors.
Dennis Christoph Harrer, Dennis Christoph Harrer, Valerie Bezler, Jordan Hartley, Wolfgang Herr, Hinrich Abken   +5 more
doaj   +1 more source